Bridgebio Pharma, INC 8-K filings

BridgeBio reports sustained positive results from a Phase 2 trial of infigratinib in children with achondroplasia, showing significant improvements in height velocity and body proportionality, and has initiated a study for hypochondroplasia.

BridgeBio Pharma announced strong first quarter 2024 financial results, highlighted by a significant increase in revenue and a substantial capital raise, alongside key clinical and regulatory advancements.

BridgeBio Pharma has launched a public offering of 8,620,690 shares of common stock at $29.00 per share, aiming to raise approximately $250 million.

BridgeBio Pharma has granted Bayer exclusive rights to develop and commercialize acoramidis in Europe, potentially earning up to $310 million in milestone payments.

BridgeBio Pharma announced positive clinical trial updates, including the acceptance of a New Drug Application for acoramidis, and secured up to $1.25 billion in capital.

BridgeBio Pharma has entered into agreements for $1.25 billion in financing, including a royalty agreement tied to acoramidis sales and a new senior secured credit facility.